logo

For the Inventor, By the Inventor

King of Prussia, PA, United States of America

Cytokine Pharmasciences, Inc.

Calculating rank
USPTO Granted Patents = 16

% Expired Patents = 37.5



Forward Citations = 44

Loading Chart...
Loading Chart...

25 inventors (with patents filed for the assignee):

goldMedal Richard J Bucala (5 out of 57 patents)

silverMedal Thais Motria Sielecki-Dzurdz (4 out of 9 patents)

bronzeMedal Yousef Al-Abed (3 out of 41 patents)

4.  Anthony Cerami (3 out of 167 patents)

5.  Michael I Bukrinsky (3 out of 21 patents)

6.  Kevin J Tracey (2 out of 94 patents)

7.  Pamela Cohen (2 out of 7 patents)

8.  Helena Schmidtmayerova (2 out of 3 patents)

9.  Robert A Mitchell (2 out of 9 patents)

10.  Jurgen Bernhagen (2 out of 5 patents)

11.  Thierry F Calandra (2 out of 5 patents)

12.  Peter Gregersen (1 out of 9 patents)

13.  Lin Leng (1 out of 5 patents)

14.  Christine N Metz (1 out of 7 patents)

15.  John A Baugh (1 out of 2 patents)


16 patents:

1. 8034840 - Guanylhydrazone salts, compositions, processes of making, and methods of using (2011-10-11),
2. 7928130 - Isoxazoline compounds having MIF antagonist activity (2011-04-19),
3. 7863334 - Guanylhydrazone compounds, compositions, methods of making and using (2011-01-04),
4. 7795314 - Protective role of semapimod in necrotizing enterocolitis (2010-09-14),
5. 7741372 - Guanylhydrazones useful for treating diseases associated with T cell activation (2010-06-22),
6. 7741057 - Method for screening for compounds using MHC class II invariant chain polypeptide and macrophage migration inhibitory factor (2010-06-22),
7. 7662843 - Isoxazoline compounds having MIF antagonist activity (2010-02-16),
8. 7517523 - Anti-MIF antibodies (2009-04-14),
9. 7491740 - Isoxazoline compounds having MIF antagonist activity (2009-02-17),
10. 7291647 - Guanylhydrazone compounds, compositions, methods of making and using (2007-11-06),
11. 7244765 - Guanylhydrazone salts, compositions, processes of making and methods of using (2007-07-17),
12. 7205107 - Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease (2007-04-17),
13. 6998238 - Method for determining MIF content (2006-02-14),
14. 6906076 - Compounds and methods of use to treat infectious diseases (2005-06-14),
15. 6774227 - Therapeutic uses of factors which inhibit or neutralize MIF activity (2004-08-10),
Company Overview
Cytokine Pharmasciences, Inc. is a biotechnology company based in King of Prussia, Pennsylvania, specializing in the development and manufacturing of innovative therapeutic solutions. The organization focuses on harnessing the power of cytokines and other biologics to address unmet medical needs across various therapeutic areas, including oncology and autoimmune diseases. With a commitment to advancing healthcare through cutting-edge research and technology, Cytokine Pharmasciences aims to improve patient outcomes and contribute to the evolving landscape of biopharmaceuticals.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

16 Patents

#11 in King of Prussia, PA

#722 in Pennsylvania

#19,944 in US

#37,887 in the World

King of Prussia, PA (US)
King of Prussia, PA, United States of America

Cytokine Pharmasciences, Inc.

Forward Citations = 44

25 inventors:

goldMedal Richard J Bucala (5 out of 57 patents)

silverMedal Thais Motria Sielecki-Dzurdz (4 out of 9 patents)

bronzeMedal Yousef Al-Abed (3 out of 41 patents)

4.  Anthony Cerami (3 out of 167 patents)

5.  Michael I Bukrinsky (3 out of 21 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cytokine Pharmasciences, Inc.. Retrieved from https://idiyas.com/company/cytokine-pharmasciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…